cipaglucosidase alfa (Pending FDA Approval)

Brand and Other Names:
  • Print
Sections

Dosing & Uses

Pompe Disease

Pending FDA approval for use in conjunction with miglustat for treatment of late onset Pompe disease

Next:

Pharmacology

Mechanism of Action

Enzyme replacement therapy; recombinant human acid alpha-glucosidase enzyme with optimized carbohydrate structures to enhance uptake into cells

Used with miglustat, a stabilizer of cipaglucosidase alfa

Previous
Next:

Images

No images available for this drug.
Previous
Next:

Patient Handout

A Patient Handout is not currently available for this monograph.
Previous
Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.